BIIB Q2 2023 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q2 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.5B-5.1% YoY

Gross Profit

$1.9B75.9% margin

Operating Income

$690M28.1% margin

Net Income

$592M24.1% margin

EPS (Diluted)

$4.07

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

$487M

Free Cash Flow

$400M

Stock-Based Comp.

$74M

Balance Sheet

Total Assets

$25.2B

Total Liabilities

$10.7B

Stockholders' Equity

$14.5B

Cash & Equivalents

$2.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.5B	$2.6B	-5.1%
Gross Profit	$1.9B	$2.1B	-11.5%
Operating Income	$690M	$936M	-26.3%
Net Income	$592M	$1.1B	-44.1%

Revenue Segments

MS Product Revenues

$1.2B43%

TYSABRI product

$483M17%

SPINRAZA

$437M15%

Fumarate

$400M14%

Interferon

$302M11%

Geographic Segments

Non-US

$1.0B57%

UNITED STATES

$801M43%